Sign Up
Stories
Sangamo Therapeutics' Gene Therapy Advancement
Share
Advancements in Cancer Treatment and Mar...
Advancements in Immunotherapy for Neurol...
Advancing ALS Treatment through Protein ...
4D Molecular Therapeutics Raises $300 Mi...
4DMT Presents Positive Interim Data
AMX0035 for PSP: Phase 3 Trial Commences
Overview
API
Sangamo Therapeutics unveils updated Phase 1/2 study results for isaralgagene civaparvovec, a gene therapy for Fabry disease, showing sustained benefits and safety profile.
Ask a question
How might the potential partnerships and financing options impact the progress and accessibility of the gene therapy?
What are the potential implications of the sustained benefits and safety profile of isaralgagene civaparvovec for the treatment of Fabry disease?
What challenges and uncertainties may exist in the development and implementation of gene therapies for rare genetic conditions?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage